|
|
Speakers 
 Mr Daniel Adams,
President and CEO,
Protein Science Corp
|
 Dr David Allison,
Medical Officer Of Health,
Health and Community Services Canada
Dr. David Allison serves the Eastern Region Integrated Health Authority (Eastern Health) in St. John’s, Newfoundland and Labrador, as Medical Officer of Health. A graduate of Queen’s University, Kingston, Ontario and a fellow of the Royal College of Physicians and Surgeons of Canada in Community Medicine, he is also a Clinical Assistant Professor with the Division of Community Health in the Faculty of Medicine of Memorial University of Newfoundland.
Dr. Allison has worked in public health settings in Saskatchewan, Alberta and New Brunswick. Additionally he has worked internationally in Nepal and Sierra Leone, Australia and New Zealand. Dr. Allison is a Co-Chair of the Canadian Coalition for Immunization Awareness and Promotion and an active member of the Canadian Public Health Association.
|
 Dr Stephen Bell,
Vice President Research and Preclinical Development,
BioSante
|
Senator Dale Bumpers,
Arent Fox
|
 Dr Oren Cohen,
Chief Medical and Scientific Officer,
Quintiles Transnational Corp.
Oren J. Cohen, MD, is Chief Medical and Scientific Officer for Quintiles Transnational. Concomitantly, he holds an appointment as clinical associate professor of medicine on the infectious diseases faculty of George Washington University Medical Center.
Joining Quintiles in 2001, Dr. Cohen served on the company’s bioterrorism preparedness committee. His industry experience is concentrated in antiviral drug development, with particular emphasis in HIV, hepatitis B and hepatitis C. Completing a fellowship at the National Institute of Allergy and Infectious Diseases, he conducted clinical HIV/AIDS research at NIAID’s Laboratory of Immunoregulation for several years. At NIAID, he served on a clinical practices panel that formulates national guidelines for the use of antiretroviral agents.
Dr. Cohen was elected to Phi Beta Kappa at Brandeis University, where he received a bachelor’s degree in biochemistry. He earned a medical degree from Duke University and completed his residency at New York Hospital/Cornell University Medical Center, where he was assistant chief resident. He is board certified in internal medicine and infectious diseases. He has written more than 50 scientific articles and book chapters. A fellow of the Infectious Diseases Society of America, he also serves as a reviewer for such highly respected medical journals as The Lancet and AIDS, among others. He has won numerous awards for his professional achievements and has presented his work at dozens of conferences around the world.
|
 Dr Timothy Cooke,
Chief Operating Officer,
Avant Immunotherapeutics
Dr. Cooke is Senior Vice President for Commercial Development at AVANT Immunotherapeutics. He was previously Chief Executive Officer of Mojave Therapeutics, a therapeutic vaccine company that was sold to Antigenics in July 2004. Dr. Cooke held a number of domestic and international marketing and sales positions in the Merck Vaccine Division and Aventis Pasteur-MSD. In 2000, he served as the vaccine industry representative to the Working Group of the Global Alliance for Vaccines and Immunization. Dr. Cooke holds a Ph.D. in bio-organic chemistry from Columbia University and an MBA from the Columbia Business School.
|
 Dr Annie De Groot,
Chief Executive Officer and Chief Scientific Officer,
Epivax
De Groot earned degrees from Smith College (BA, 1978) and the Pritzker School of Medicine at the University of Chicago (MD, 1983). She was trained in internal medicine at Tufts New England Medical Center (1986), and then went on to complete additional training in immunoinformatics and vaccine research under Jay Berzofsky at the National Institutes of Health (1989). Following her fellowship at the NIH, she returned to Tufts NEMC for clinical training in infectious disease (1991). She became board certified in Internal Medicine in 1986 and in Infectious Disease in 1992. In 1992, she joined the faculty of the Brown University Medical School, where she opened the TB/HIV Research Laboratory. De Groot licensed the EpiMatrix vaccine design technology from her laboratory at Brown and established EpiVax, a bioinformatics and vaccine design company in 1998. She teaches undergraduate students vaccinology at Brown University and provides clinical care to patients at the Rhode Island TB clinic and the Rhode Island Free Clinic. She is founder and Co-Chief editor of Infectious Diseases in Corrections report (an on-line electronic journal, established 1998) and founder and Scientific Director of the GAIA Vaccine Foundation (501c3, 2002). De Groot has received uninterrupted federal funding for her research activities through multiple NIH (K08, R21, R01, SBIR) and foundation grants since 1989. She has published more than 60 articles and chapters describing the development of epitope-driven vaccines and the application of immunoinformatics tools. In addition to her active research on vaccines for HIV, TB, Tularemia, Smallpox and EBV, she is a pioneer in the field of deimmunizing protein therapeutics. She was the recipient of a National Foundation for Infectious Diseases-Eli Lilly Award, two Rhode Island Foundation awards and a Commercial Innovation Award (from the Rhode Island Center for Cellular Medicine). More recently, she was recognized as one of the “Best and the Brightest” in Science and Technology by Esquire Magazine (2003) and Rhode Island Woman Physician of the Year (2006) for her work on the GAIA HIV vaccine.
|
 Mr John Dwyer,
Counsel,
Arent Fox
Mr. Dwyer comes to Arent Fox with 20 years experience in starting, financing and growing early stage, venture backed health care companies. His practice will focus on advising clients on the many regulatory and transactional legal issues faced by drug, device, and healthcare services companies when they experience accelerating growth.
Prior to joining Arent Fox, Mr. Dwyer was CEO of a venture backed specialty pharmacy distribution company. Before that assignment, Mr. Dwyer founded and sold a company that provides software solutions and services for improving treatment planning and care delivery for large managed care organizations and hospitals.
Mr. Dwyer previously served as a principal and managing director in a mid-Atlantic investment bank and began his career as an associate with Arent Fox. Mr. Dwyer currently serves on the Boards of a number of private and not-for-profit organizations including CodeRyte, Inc. and the Trust for America’s Health. Mr. Dwyer is a graduate of Marquette University and the Cornell University Law School.
|
 Dr Ronald Ellis,
Senior Vice President, Development, and General Manager,
ID Biomedical Corporation
|
Dr Renata Engler,
Colonel, Chief, Allergy- Immunology Department,
Walter Reed Medical Center
|
 Dr Philip Gomez,
Director Vaccine Production Programme,
VRC, NIAID, NIH
|
 Dr Lance Gordon,
Former President and CEO Vaxgen,
Independent Advisor
Dr Lance Gordon has more than 20 years of experience in the vaccine industry, developing both vaccine products and companies. Prior to joining VaxGen, Dr Gordon served as founding CEO and a member of the Board of Directors of two vaccine companies, OraVax and North American Vaccines. He was also the CEO of North American’s predecessors, American Vaccine Corp and Selcore, Inc. During the 1980’s, Dr. Gordon served a seven-year tenure at Connaught where he was Director of Viral and Bacterial vaccines research and the inventor of ProHibit® a vaccine for infant meningitis, the first bacterial conjugate vaccine to receive FDA approval. After leaving Connaught, he served as a medical director at E.R. Squibb where he designed and implemented clinical pharmacology programs for infectious and inflammatory disease products and candidates.
|
Ms Susan Gorman,
Associate Director for Science,
CDC
|
 Dr John Gotto,
Senior Director, Global Business Development,
Wyeth Vaccines
|
 Mr Michel Greco,
Independent Vaccine Expert,
Independant Vaccine Expert
Michel Greco has had a long and successful career in the industry, both in pharmaceuticals first, with the former Rhone-Poulenc Group, and in the vaccine area for the last 15 years. From 1988 to 1993, through successive mergers and acquisitions, he had senior management responsibilities at Institut Mérieux, then Pasteur Mérieux Connaught. From 1994 to 1998, he was President and CEO of Pasteur Mérieux MSD (a European joint venture between Pasteur Mérieux and Merck). Since 1998 and until the beginning of 2003, he was President and COO, then Deputy CEO and member of the Board of Aventis Pasteur. Michel Greco is presently member of the Board of a number of biotechnology companies and of non-profit international institutions.
|
 Dr Luc Hessel,
Executive Director, Medical and Public Affairs, Europe,
Sanofi pasteur MSD
Dr Luc Hessel is Executive Director, Medical and Public Affairs, Europe, at Sanofi Pasteur MSD, the European Joint Venture between Sanofi Pasteur and Merck & Co., leading companies in vaccines and biotechnology products. He graduated in medicine from the University of Bordeaux in 1976. His professional background includes 13 years of clinical and academic activities in Internal Medicine and Public Health at the University Hospital in Limoges, France. Since 1986, he worked at Sanofi Pasteur in clinical research and development of new vaccines and other biopharmaceuticals. At Sanofi Pasteur, he then served as Director of Medical Affairs and Head of the Pharmacovigilance Department between 1992 and 1996. From 1997 to 2001, Dr. Hessel had responsibility for managing the medical function at Sanofi Pasteur MSD, and coordinating the company’s medical and clinical activities. Since April 2002 he is in charge of medical and public affairs, covering a broad range of activities, including medical expertise for online and new vaccines, relationship with governments and international institutions, pharmacovigilance and risk management. Dr. Hessel is currently chairman of the Influenza Pandemic Working Group of the European Vaccine Manufacturers (EVM) a specialised group within the European Federation of Pharmaceutical Industry Associations (EFPIA), and is member of the Biologicals and Vaccines Committee of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), where he chairs the Influenza Vaccine Supply International Task Force.
|
 Dr Robert House,
Chief Operating Officer,
DVC LLC, A CSC Company
|
 Dr Allan Jarvis,
Senior Vice President, Corporate Development,
sanofi pasteur
Allan Jarvis is currently Senior Vice President, Corporate Development at Aventis Pasteur, a Division of Aventis Pharmaceuticals. In that capacity he is responsible for the Business Development, Strategic Planning and Process Efficiency and Cost Effectiveness functions. He oversees AvP’s worldwide Corporate Development function and is responsible for managing the company’s growth through alliances, joint-ventures, partnerships, mergers, acquisitions, and the licensing of products and technology. Prior to this, he was Vice President, Business Development and Strategy for the Vaccine Business Unit of Wyeth Pharmaceuticals.
Allan received his PhD in Molecular Genetics from the University of California and held NIH Post-Doctoral Fellowships from 1976-1980 at Sloan Kettering Cancer Institute and the Worcester Foundation for Experimental Biology. In 1980, he co-founded Damon Biotech, Inc. where he held diverse positions of increasing responsibility from Manager, Molecular Biology to Vice President, Research and Vice President Business Development. From 1990 to 1992, he worked at Abbott Laboratories, Inc., as Director, Business Development. In 1992 he joined Repligen Corp. in the dual role of Vice President, Business Planning for the parent company and Sr. Vice President, Commercial Development for its wholly owned subsidiary, Amira, Inc. His primary areas of business focus include: strategic planning, valuing products and technology, negotiations and partnership management.
|
 Dr Niamh Kinsella,
Assoicate Director of Regulatory Affairs,
ERA Consulting
|
 Ms Fran Lessans,
President and Chief Executive Officer,
Passport Health
As founder, president and CEO of PASSPORT HEALTH?, Fran brings over 29 years of medical and management experience to her clients. Before founding PASSPORT HEALTH?, Fran worked in a variety of clinical settings as a registered nurse, educator and health care administrator. Fran’s business acumen is known in the community, as she has successfully turned multiple troubled organizations into profitable ventures. In 2005 she was awarded the Innovator of the Year award by the Maryland Department of Business & Economic Development and in 2006 won the Ernst & Young Entrepreneur of the Year award for the Maryland region.
|
 Mr Mark Leuchtenberger,
President and CEO,
Therion Biologics
Mark Leuchtenberger joined Therion as President and CEO in 2002 from Biogen, where he served as Vice President, International. In this capacity, he led all commercial operations outside of North America. Mr. Leuchtenberger joined Biogen in 1990 and served as Program Executive for Biogen’s commercial products Amevive® and Avonex®. In the latter role, Mr. Leuchtenberger was responsible for managing the late-stage development, registration, marketing and North American launch of Avonex®. During his tenure at Biogen, he held several senior positions, including Vice President of Sales, Marketing and Business Development, where he oversaw the company's global market, licensing and strategic partnership activities. Prior to Biogen, he worked as a Senior Consultant at Bain and Company specializing in healthcare. Mr. Leuchtenberger received an M.B.A. from the Yale School of Management and a B.A. from Wake Forest University.
|
 Mr Clement Lewin,
Vice President, Biodefense and Policy,
Acambis
Clement Lewin is Vice President of Government Affairs and Strategy at Acambis. Prior to taking up his position, Clem was at Chiron Vaccines as Vice President Government Affairs & Immunization Policy for the US and Vice President, Strategic Planning & Business Intelligence for the business unit based at global headquarters in the United Kingdom. Clem obtained his BSc and PhD from the University of London. After 5 years as a Research Fellow at the Universities of London and Edinburgh focusing on mechanisms of action and resistance to antibiotics he obtained an MBA with distinction from Cornell University. He then joined the life sciences practice of Pittiglio Rabin Todd & McGrath specializing in product development issues. Prior to joining Chiron, Clem was with Merck Vaccines Division in a variety of domestic and international marketing positions and with Bayer Pharmaceuticals as Director of Global Scientific Affairs for their anti-infective franchise. He currently serves as the BIO liaison representative to the Advisory Committee on Immunization Practices and on the advisory boards of Bio Ventures for Global Health and the Alliance for Biosecurity.
|
Dr Scott McMillan,
Director, Manufacturing Operations,
Avant Immunotherapeutics
|
Dr Ana Menendez,
Senior Director of Bioassys and Biosafety testing,
Cardinal Health
|
Dr Annold Monto,
Founding Director,
The University of Michigan Bioterrorism Prepardness Initative
|
Mr Tony Mulcahy,
Cobra Biomanufacturing
|
 Dr Richard Nolan,
Senior Advisor to the Director, Strategic National Stockpile,
CDC
|
 Dr Jeanne Novak,
CEO and Prinicapal Consultant,
CBR International Corp
Jeanne M. Novak, Ph.D. is the CEO and Principal Consultant of CBR International Corp. which provides high-level strategic, product and clinical development consulting for the pharmaceutical and biotechnology industries. Dr. Novak has over 20 years of experience in pharmaceutical development and is a recognized leader in the areas of vaccines and immunology. Prior to consulting, Dr. Novak was an FDA Senior Reviewer in the Center for Biologics Evaluation and Research (CBER), and conducted scientific research at United States Army Medical Research Institute of Infectious Diseases at Fort Detrick. Dr. Novak received a Ph.D. in Experimental Pathology and a B.S. in Biology from the University of Utah. She is on the editorial board of Clinical and Diagnostic Laboratory Immunology, and is co-author of numerous scientific and regulatory publications. Dr. Novak has presented several clinical and regulatory seminars at professional conferences sponsored by RAPS, DIA, IBC and others. She is an active member of the Regulatory Affairs Professionals Society (RAPS), ASM, the Drug Information Association (DIA), the International Association of Biological Standardization, International Society of Pharmaceutical Engineers (ISPE), American Society for Quality (ASQ), International Association for Biologicals and PDA, an International Association for Pharmaceutical Science and Technology.
|
 Dr Helene Pora,
Vaccine Application Development Director,
Pall Life Sciences
Dr Hélène Pora is Vaccine Application Development director with Pall LIfe Sciences , where she has the worldwide responsibility for the development of improved separation and purification solutions for the vaccine and gene therapy market. She is also heavily involved in the development of improved single use technologies and related scale-up aspects. Hélène has more than 20 years of experience working for the pharmaceutical and the separation industries, the last 15 years with Pall Corporation. She holds an Engineering Degree in Biochemistry (with Molecular Biology) from the Institut National Agronomique (France) and a PhD in Biochemistry ( on protein engineering and purification) from the University of Orsay (France). Hélène Speaks regularly at conferences about improved separation technologies for the biotechnology and biopharmaceutical industry.
|
 Dr Richard Roden,
Associate Professor, Pathology,
Johns Hopkins University
|
 Dr Una Ryan,
President and CEO,
Avant Immunotherapeutics
Una S. Ryan, Ph.D., O.B.E. is President and CEO of AVANT Immunotherapeutics, Inc., a publicly traded biopharmaceutical company developing vaccines and immunotherapeutics for cardiac surgery, cholesterol management, biodefense, travelers, food safety, and global health. AVANT is developing a portfolio of oral vaccines designed to provide rapid protection following a single dose. AVANT’s rotavirus vaccine is marketed by GlaxoSmithKline Biologicals as Rotarix® in the European Union and over 65 countries. Dr. Ryan has led the expansion of AVANT’s vectored bacterial vaccines programs, completed three company acquisitions, and established the company’s new manufacturing facility in Fall River, Massachusetts. She is also Research Professor of Medicine at the Boston University School of Medicine and serves on its Board of Visitors. She is immediate past Chair of the Massachusetts Biotechnology Council, serves on its Board, as well as the Boards of the Biotechnology Industry Organization, the New England Healthcare Institute, the Board of Associates of the Whitehead Institute, and the Board of Directors of IQuum, Inc. Dr. Ryan is a member of the Strategy & Policy Council of the MIT Center for Biomedical Innovation and serves as a member of the Business Advisory Board of BIO Ventures for Global Health. In 2002 Her Majesty Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for her services to the research, development and promotion of biotechnology.
|
 Dr Jerald C. Sadoff,
President and CEO,
Aeras Global TB Vaccine Foundation
Jerald C. Sadoff became President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation in June 2003.
Dr. Sadoff has spent more than three decades developing vaccines for dozens of diseases, from chicken pox to malaria. He came to Aeras from Merck, where he was the Executive Director of Clinical Development of Vaccines. While at Merck, Dr. Sadoff led the efforts to develop and obtain licensure for a preventive vaccine against hepatitis A, a liquid form of the Haemophilus influenza type B (Hib) vaccine, and a 4-degree stable form of the chicken pox vaccine. He also led efforts to obtain licenses for three combination vaccines: one prevents hepatitis B and Hib, one licensed in Europe, prevents six different diseases, including whooping cough, polio, tetanus, diphtheria, hepatitis B and Hib, and recently a MMR/varicella combination. He also played a leading role in Merck’s HIV, rotavirus, herpes zoster, and human papilloma virus programs.
Before joining Merck, Dr. Sadoff was Director, Division of Communicable Diseases and Immunology, at the Walter Reed Army Institute of Research, where he worked on vaccines against bacterial, viral and parasitic diseases, including sepsis, gonorrhea, cholera, shigella, dengue, HIV and malaria. He attained the rank of Colonel in the US Medical Corps.
Throughout his career, he has chaired or served on over 20 national and international task forces, initiatives, consulting groups and advisory boards. Currently, he is Chair of the USAID Malaria Vaccine Scientific Consultants Group and Chair of the NIH/NIAID Oversight Task Force for Malaria. He serves on the NIAID AIDS Vaccine Research Working Group and the Scientific Advisory Board of the International AIDS Vaccine Initiative.
|
 Ranajit Sen,
Advisor - Strategic Planning & Business Development,
Shantha Biotechnics Limited
Looking after Strategic Planning and Business Development(in-licensing & out-licensing).Have over 25 years of experience in the pharma industry,with the last 8 years with a pioneering Biologics company,Shantha Biotechnics,located in India.
|
 Mr Andrew Sheldon,
President and CEO,
Medicago
|
Dr Rahul Singhvi,
President and CEO,
Novavax Inc
|
 Dr Doris Snow,
Director, Regulatory Affairs,
DVC LLC, A CSC Company
Doris M. Snow, PhD., is an Associate Director of Regulatory Affairs for DynPort Vaccine Company, LLC (DVC), A CSC Company, where she is responsible for developing and implementing regulatory strategy for vaccines. She has over 10 years of experience in biochemistry, regulatory affairs and research with expertise in new product development. Prior to joining DVC, Dr. Snow held positions in quality assurance and regulatory affairs overseeing the development of cancer therapeutics and biodefense vaccines through the IND stage. Dr. Snow received a bachelor's degree in biology from the University of Virginia and a Ph.D. in biological chemistry from the Johns Hopkins University School of Medicine.
|
 Dr Patrick Squiban,
Chief Medical Officer and Vice President Medical and Regulatory Affairs,
Innate Pharma
|
Indresh Srivastava,
Associate Director,
Chiron Vaccines
|
 Philippe Stas,
Chief Operating Officer,
AlgoNomics
Dr. Philippe Stas is chief operating officer of AlgoNomics, a Belgium based biotech company specialized in immunogenicity monitoring and assessment. Since 1999, Philippe has been responsible for business development, project management and operations at the company.
From 1990 till 1997, Philippe has been active in antibody engineering, immunology and bioinformatics research at the University of Brussels. After performing bioinformatics research at PE Genscope (a Perkin Elmer company, CA), he joined the team for the creation of AlgoNomics in 1999. Since 2002, the company built out an industry standard for predicting and measuring T-cell driven immunogenicity. Philippe holds an M.Sc.E. in biotechnology, a Master in IT, an MBA in part and is chairman of the Belgian Association of Bioindustries bio.be
|
 Mr Fredrik Sundberg,
Director Global Pharma, CO,
Biacore AB
As Director of Market Development for the pharmaceutical and biotech industrial sector, Mr. Sundberg is responsible for expanding the application of label free protein interaction analysis throughout drug discovery and development, in-process and quality control workflows. He has specialist knowledge in the area of validation support and frequently provides GxP (GLP, GCP, GMP) training to the pharmaceutical industry. He has conducted several pharmaceutical development projects, completed validation studies for a variety of analytical instruments and process equipment, and produced more than 100 IQ/OQ/PQs for different pharmaceutical companies worldwide. Mr. Sundberg is the author of several publications and articles in the field of using biosensor technology for productivity improvements and GxP quality control and has presented at numerous premier conferences. On a regular basis, he lectures and discusses regulatory issues with organizations from both industrial and government authorities and advises on in-house development projects. He holds an MSc in Chemical Engineering from the Royal Institute of Technology in Stockholm, Sweden.
|
Dr Litjen Tan,
Director Infectious Disease, Immunology and Molecular Medicine,
American Medical Association
|
 Dr. Frederic Triebel,
Scientific and Medical Director,
Immutep S.A.
Pr. Frédéric TRIEBEL is a founder and the Scientific and Medical Director of Immutep S.A.. He received his M.D. degree in 1981, was trained as a clinical haematologist and obtained his Ph.D. in Immunology in 1986. He was nominated Professor in Immunology in 1990 at the Paris-Sud University and worked for 16 years at Institut Gustave Roussy (IGR) where he conducted basic science and clinical research. He discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule in the field of therapeutic vaccines. He was Director of an INSERM Unit from 1991 to 1996 at IGR and successfully developed several research programs in immunogenetics, leading to 125 publications.
|
 Dr Jeffrey Ulmer,
Head, Immunology and Cell Biology,
Novartis Vaccines and Diagnostics
Dr. Jeffrey Ulmer received his B.Sc. with honors from the Department of Chemistry at the University of Regina in 1978 and was the recipient of the Merit Award of the Society of Chemical Industry. He received his Ph.D. in biochemistry from McGill University in 1985 and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories he conducted seminal studies on DNA vaccines, and is currently Head, Immunology & Cell Biology at Novartis Vaccines and Diagnostics. His group is responsible for discovery and technology development of vaccines and adjuvants; and production, purification, and characterization of recombinant protein-based vaccines. He has published over 150 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy and Human Vaccines, and is on the Scientific Advisory Committee of the Duke University Multiscale Integrative Immunology for Adjuvant Development program.
|
 Dr Kenneth Yates,
President,
DelSite Biotechnologies Inc
Dr. Yates is President of DelSite Biotechnologies, Inc., a drug delivery company headquartered in Irving, Texas. He has been president of DelSite since its inception in 2001 as a wholly-owned subsidiary of Carrington Laboratories.
Prior to co-founding DelSite, Dr. Yates was Vice President, Research and Development at Carrington, where since 1990 he served in various capacities in research and development. He is Adjunct Assistant Professor at the University of Texas Southwestern Medical School and is co-inventor of DelSite’s four issued patents relating to the GelSite® polymer.
Dr. Yates has extensive experience in the formulation, development and regulation of human and veterinary biological and device products, including the successful commercialization of several topical and oral indications for pain and wound management.
Dr. Yates attended Texas A&M University where he received an M.S. in physiology and pharmacology in 1975 and a Doctor of Veterinary Medicine in 1977.
|
 Michel Zaffran,
Deputy Executive Secretary and Chief Technical and Policy Officer,
GAVI Alliance
Michel Zaffran is a French National , Born in Algeria in 1956. He is an engineer from Ecole Centrale, France and TH, Darmstadt, Germany with subsequent training in Tropical Epidemiology at the Heidelberg University.
After 2 years in Morocco, with the French Government, he joined GRET, a French NGO for which he worked in Burkina Faso and the Democratic Republic of Congo (formerly called Zaire)
Michel Zaffran then spent 18 years with WHO Vaccines and Immunization Department, in cold chain and logistics, overseeing the work on quality of immunization services and as Programme Manager in charge of the departmental strategic planning. His last assignment with WHO was as Coordinator of the Access to Technologies team where he was leading efforts in Vaccine Quality, Vaccine Management, Vaccine Supply and Immunization Financing. From 1998 to 2003 he was the WHO representative on the Working Group which helped design and launch GAVI.
Since February 2006 Michel Zaffran is Deputy Executive Secretary of the GAVI alliance, with responsibility over the Technical/Policy areas
|
|
|
|
